Head-to-head evidence
dulaglutide vs HDG1901
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
dulaglutide · Trulicity
Marketed by Eli Lilly
NCT01394952 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial involving 9,901 participants. The hard clinical primary endpoint was met: 594 dulaglutide participants versus 663 placebo participants experienced a composite cardiovascular event, with a hazard ratio of 0.88 (p=0.026).
Next expected readout: April 2027 · NCT07537088 (registry estimate)
HDG1901
Developed by Hangzhou Zhongmei Huadong Pharmaceutical
NCT06739044 · Phase 3 · completed
The trial randomized 494 participants to HDG1901 or active Ozempic treatment, but neither participants nor investigators were blinded. Its primary endpoint was change in HbA1c, a surrogate measure, and the registry does not report whether the comparison met its objective, supporting a moderate evidence grade.
Caveat: source is secondary industry coverage that does not cite the trial registry number; attribution rests on sponsor/program match only.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: dulaglutide's landscape · HDG1901's landscape